SAN FRANCISCO–Applaud Medical, Inc. (Applaud), an emerging leader in the treatment of kidney stones, today announced that a new U.S. patent titled “Phospholipid compounds and formulations” (patent number 10,953,023) was granted to the company by the United States Patent and Trademark Office (USPTO) on March 23, 2021. The patent covers strategies for manufacturing, preparing and using phospholipid compounds, formulations and associated microspheres in the treatment of nephrolithiasis or kidney stone disease.
“This patent builds on previous patents associated with our Acoustic Enhancer technology and supports our strategy to build a strong intellectual property portfolio,” stated Thomas Kenny, PhD, Co-Founder and Chairman of Applaud Medical.
Applaud Medical’s Acoustic Enhancer technology is designed to be used in conjunction with Ureteroscopy with Laser Lithotripsy (URS-LL) for the fragmentation of calcium-based urinary stones of at least 6mm and not more than 20mm in diameter that are obstructing or deemed to present a significant risk of future obstruction by a urologist or other qualified physician, which can place patients at risk of future sepsis, chronic kidney disease, or end-stage renal disease. The Acoustic Enhancer microparticles generate additional stone-fragmenting shockwaves when used during a laser lithotripsy procedure.
About Applaud Medical, Inc.
Applaud is a privately held company founded in 2014 which aims to improve treatment methods, patient experiences and medical costs for all patients experiencing the effects of kidney stones. The Company is developing the Applaud Acoustic Enhancer, an innovative technology designed to enhance Ureteroscopy with Laser Lithotripsy (URS-LL) in the fragmentation of kidney stones. The Company is also actively conducting a prospective, multicenter, randomized, double-blind study (NCT04563039) for the Acoustic Enhancer when used in conjunction with URS-LL.